Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Cboe CA - Delayed Quote CAD

Gilead Sciences, Inc. (GILD.NE)

21.61
+0.06
+(0.28%)
At close: May 2 at 2:43:12 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
28,735,000
28,754,000
27,116,000
27,281,000
27,305,000
Cost of Revenue
6,239,000
6,251,000
6,498,000
5,657,000
6,601,000
Gross Profit
22,496,000
22,503,000
20,618,000
21,624,000
20,704,000
Operating Expense
9,310,000
11,998,000
11,808,000
10,650,000
9,847,000
Operating Income
13,186,000
10,505,000
8,810,000
10,974,000
10,857,000
Net Non Operating Interest Income Expense
-702,000
-696,000
-568,000
-829,000
-1,001,000
Other Income Expense
-5,660,000
-9,119,000
-1,383,000
-4,330,000
-1,578,000
Pretax Income
6,825,000
690,000
6,859,000
5,814,000
8,278,000
Tax Provision
860,000
211,000
1,247,000
1,248,000
2,077,000
Net Income Common Stockholders
5,965,000
480,000
5,665,000
4,592,000
6,225,000
Diluted NI Available to Com Stockholders
5,965,000
480,000
5,665,000
4,592,000
6,225,000
Total Operating Income as Reported
8,221,000
1,662,000
7,605,000
7,330,000
9,918,000
Total Expenses
15,549,000
18,249,000
18,306,000
16,307,000
16,448,000
Net Income from Continuing & Discontinued Operation
5,965,000
480,000
5,665,000
4,592,000
6,225,000
Normalized Income
10,543,847.62
6,816,315
6,787,296
7,969,771.93
6,928,311
Interest Income
--
281,000
376,000
106,000
--
Interest Expense
983,000
977,000
944,000
935,000
1,001,000
Net Interest Income
-702,000
-696,000
-568,000
-829,000
-1,001,000
EBIT
7,808,000
1,667,000
7,803,000
6,749,000
9,279,000
EBITDA
7,808,000
4,434,000
10,496,000
8,852,000
11,329,000
Reconciled Cost of Revenue
6,239,000
6,251,000
6,498,000
5,657,000
6,601,000
Reconciled Depreciation
--
2,767,000
2,693,000
2,103,000
2,050,000
Net Income from Continuing Operation Net Minority Interest
5,965,000
480,000
5,665,000
4,592,000
6,225,000
Total Unusual Items Excluding Goodwill
-5,239,000
-9,117,000
-1,372,000
-4,301,000
-939,000
Total Unusual Items
-5,239,000
-9,117,000
-1,372,000
-4,301,000
-939,000
Normalized EBITDA
13,047,000
13,551,000
11,868,000
13,153,000
12,268,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-660,152.38
-2,780,685
-249,704
-923,228.07
-235,689
12/31/2021 - 4/29/2025

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AMGN.NE AMGEN CDR (CAD HEDGED)
21.18
-3.38%
 
ROG.NE Roche Holding AG
21.31
+0.47%
 
NVON.NE NOVO NORDISK CDR (CAD HEDGED)
7.41
+3.64%
 
LLY.NE Eli Lilly and Company
30.45
+3.85%
 
AMGN Amgen Inc.
281.22
-0.90%
 
OGN Organon & Co.
9.59
+1.48%
 
JNJ Johnson & Johnson
156.12
+1.07%
 
NVO Novo Nordisk A/S
69.23
+5.53%